Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters20130801
Title: The structure of the ternary Eg5-ADP-ispinesib complex.
Journal: Acta crystallographica. Section D, Biological crystallography20121001
Title: Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.
Journal: Journal of medicinal chemistry20120223
Title: Protein-based identification of quantitative trait loci associated with malignant transformation in two HER2+ cellular models of breast cancer.
Journal: Proteome science20120101
Title: Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.
Journal: PloS one20120101
Title: Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.
Journal: Journal of medicinal chemistry20111013
Title: A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Journal: Investigational new drugs20110601
Title: The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Journal: Head & neck oncology20110101
Title: Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.
Journal: Frontiers in oncology20110101
Title: A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Journal: Pediatric blood & cancer20101215
Title: Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.
Journal: Biochemistry20100928
Title: Functional characterisation and drug target validation of a mitotic kinesin-13 in Trypanosoma brucei.
Journal: PLoS pathogens20100801
Title: Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20100115
Title: Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Journal: Pediatric blood & cancer20091215
Title: Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
Journal: Biochemistry20091124
Title: A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
Journal: Cancer chemotherapy and pharmacology20090201
Title: KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
Journal: BMC cancer20090101
Title: Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Journal: Clinical genitourinary cancer20080901
Title: Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Journal: Anti-cancer agents in medicinal chemistry20080801
Title: Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator.
Journal: Journal of the American Chemical Society20080618
Title: A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Journal: Investigational new drugs20080601
Title: Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Journal: Investigational new drugs20080601
Title: A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
Journal: Investigational new drugs20080601
Title: Mechanism of inhibition of human KSP by ispinesib.
Journal: Biochemistry20080318
Title: A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Journal: British journal of cancer20080311
Title: A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
Journal: Clinical genitourinary cancer20080301
Title: Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
Journal: Cancer journal (Sudbury, Mass.)20080101
Title: ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
Journal: Nature chemical biology20071101
Title: Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors.
Journal: Bioorganic & medicinal chemistry letters20070701
Title: American Chemical Society--233rd National Meeting. Kinesin spindle protein inhibitors. 25-29 March 2007, Chicago, IL, USA.
Journal: IDrugs : the investigational drugs journal20070501
Title: A Bayesian population PK-PD model of ispinesib-induced myelosuppression.
Journal: Clinical pharmacology and therapeutics20070101
Title: Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line.
Journal: BMC cancer20060101
Title: Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, And Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The European Cancer Conference, Paris, France, October 30-November 3, 2005.
Journal: Clinical genitourinary cancer20051201
Title: Lad L, et al. Mechanism of inhibition of human KSP by ispinesib. Biochemistry. 2008 Mar 18;47(11):3576-85.
Title: Purcell JW, et al. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin Cancer Res. 2010 Jan 15;16(2):566-76.
Title: Davis DA, et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer. 2006 Jan 24;6:22.
